Human CYFIP2/DEE65/EIEE65 ORF/cDNA clone-Lentivirus plasmid (NM_001291722.2)

Cat. No.: pGMLV001652
Size: 10 µg
Concentration: generally 0.5ug/ul, usually not less than 0.3ug/ul
Leading Time: 3-7 working days

Pre-made Human CYFIP2/DEE65/EIEE65 Lentiviral expression plasmid for CYFIP2 lentivirus packaging, CYFIP2 lentivirus production, overexpression stable cell line development, cell transient transfection and gene delivery targeting T/B/NK cells, macrophages, cardiomyocytes, hepatocytes, and neurons.

Our GM-Lentiviral vector is seamlessly integrated with the GM lentivirus packaging system. Discover more about the GM lentivirus packaging system.

pdf Datasheet
pdf MSDS
pdf Terms of Use
Target products collection

Go to CYFIP2/DEE65 products collection>>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

Purchase
Total Price: $1834.8
Shipping fee: Limited-time free
For payment issues, contact us.


Product Description

Catalog ID pGMLV001652
Gene Name CYFIP2
Accession Number NM_001291722.2
Gene ID 26999
Species Human
Product Type Lentivirus plasmid (overexpression)
Insert Length 3837 bp
Gene Alias DEE65,EIEE65,PIR121
Fluorescent Reporter Null
Mammalian Cell Selection Puromyocin
Fusion Tag 3xflag (C-Terminal)
Promoter CMV
Resistance Amplicin
ORF Nucleotide Sequence ATGACCACGCACGTCACCCTGGAAGATGCCCTGTCCAACGTGGACCTGCTTGAAGAGCTTCCCCTCCCCGACCAGCAGCCATGCATCGAGCCTCCACCTTCCTCCATCATGTACCAGGCTAACTTTGACACAAACTTTGAGGACAGGAATGCATTTGTCACGGGCATTGCAAGGTACATTGAGCAGGCTACAGTCCACTCCAGCATGAATGAGATGCTGGAGGAAGGACATGAGTATGCGGTCATGCTGTACACCTGGCGCAGCTGTTCCCGGGCCATTCCCCAGGTGAAATGCAACGAGCAGCCCAACCGAGTAGAGATCTATGAGAAGACAGTAGAGGTGCTGGAGCCGGAGGTCACCAAGCTCATGAAGTTCATGTATTTTCAGCGCAAGGCCATCGAGCGGTTCTGCAGCGAGGTGAAGCGGCTGTGCCATGCCGAGCGCAGGAAGGACTTTGTCTCTGAGGCCTACCTCCTGACCCTTGGCAAGTTCATCAACATGTTTGCTGTCCTGGATGAGCTAAAGAACATGAAGTGCAGCGTCAAGAATGACCACTCTGCCTACAAGAGGGCAGCACAGTTCCTGCGGAAGATGGCAGATCCCCAGTCTATCCAGGAGTCGCAGAACCTTTCCATGTTCCTGGCCAACCACAACAGGATCACCCAGTGTCTCCACCAGCAACTTGAAGTGATCCCAGGCTATGAGGAGCTGCTGGCTGACATTGTCAACATCTGTGTGGATTACTACGAGAACAAGATGTACCTGACTCCCAGTGAGAAACATATGCTCCTCAAGGTGATGGGCTTTGGCCTCTACCTAATGGATGGAAATGTCAGTAACATTTACAAACTGGATGCCAAGAAGAGAATTAATCTTAGCAAAATTGATAAATTCTTTAAGCAGCTGCAGGTGGTGCCCCTTTTCGGCGACATGCAGATAGAGCTGGCCAGATACATTAAGACCAGTGCTCACTATGAAGAGAACAAGTCCAAGTGGACGTGCACCCAGAGCAGCATCAGCCCCCAGTACAATATCTGCGAGCAGATGGTTCAGATCCGGGATGACCACATCCGCTTCATCTCCGAGCTCGCTCGCTACAGCAACAGTGAGGTGGTGACGGGCTCAGGGCTGGACAGCCAGAAGTCAGACGAGGAGTATCGCGAGCTCTTCGACCTAGCCCTGCGGGGTCTGCAGCTTCTATCCAAGTGGAGCGCCCACGTCATGGAGGTGTACTCTTGGAAGCTGGTTCATCCCACAGACAAGTTCTGCAACAAGGACTGTCCTGGCACCGCGGAGGAATATGAGAGAGCCACACGCTACAATTACACCAGTGAGGAAAAATTTGCCTTCGTTGAGGTGATCGCCATGATCAAAGGCCTGCAGGTGCTCATGGGCAGGATGGAGAGCGTCTTCAACCAGGCCATCAGGAACACCATCTACGCGGCATTGCAGGACTTCGCCCAGGTGACGCTGCGTGAGCCCCTGCGGCAGGCGGTACGGAAGAAGAAGAATGTCCTCATCAGCGTCCTACAGGCAATTCGAAAGACCATCTGTGACTGGGAGGGAGGGCGAGAGCCCCCTAATGACCCATGCTTGAGAGGGGAGAAGGACCCCAAAGGTGGATTTGATATCAAGGTGCCCCGGCGTGCTGTGGGGCCATCCAGCACACAGGCCTGCCAGTGGTCCCCGAGGGCTTTGTTTCACCCCACTGGTGGCACACAGGGCCGAAGAGGCTGCCGATCCCTGCTGTACATGGTGCGGACCATGCTTGAATCACTCATTGCAGACAAAAGCGGCTCCAAGAAGACCCTGAGGAGCAGCCTGGATGGACCCATTGTCCTCGCCATAGAGGACTTTCACAAACAGTCCTTCTTCTTCACACATCTGCTCAACATCAGTGAAGCCCTGCAGCAGTGTTGTGACCTCTCCCAGCTCTGGTTCCGAGAATTCTTCCTGGAGTTAACCATGGGCCGACGAATCCAGTTCCCCATCGAGATGTCCATGCCCTGGATTCTAACGGACCATATCCTGGAAACCAAAGAACCTTCCATGATGGAGTATGTCCTCTACCCTCTGGATCTGTACAACGACAGCGCCTACTATGCTCTGACCAAGTTTAAAAAGCAGTTCCTGTACGATGAGATAGAAGCTGAGGTGAACCTGTGTTTTGATCAGTTTGTCTACAAGCTGGCAGACCAGATCTTTGCTTACTACAAAGCCATGGCTGGCAGTGTCCTGTTGGATAAACGTTTTCGAGCTGAGTGTAAGAATTATGGCGTCATCATTCCGTATCCACCGTCCAATCGCTATGAAACACTGCTGAAGCAGAGACACGTCCAGCTGTTGGGTAGATCAATTGACTTGAACAGACTCATTACCCAGCGCATCTCTGCCGCCATGTATAAATCCTTGGACCAAGCTATCAGCCGCTTTGAGAGTGAGGACCTGACCTCCATTGTGGAGCTGGAGTGGCTGCTGGAGATTAACCGGCTCACGCATCGGCTGCTCTGTAAGCATATGACGCTGGACAGCTTCGATGCCATGTTCCGAGAGGCCAATCACAATGTGTCCGCCCCCTATGGCCGTATCACCCTGCATGTCTTCTGGGAACTGAACTTTGACTTTCTCCCCAACTACTGCTACAATGGGTCCACTAACCGTTTTGTGCGGACTGCCATTCCTTTCACCCAAGAACCACAACGAGACAAACCTGCCAACGTCCAGCCTTATTACCTCTATGGATCCAAGCCTCTCAACATTGCCTACAGCCACATCTACAGCTCCTACAGGAATTTCGTGGGGCCACCTCATTTCAAGACTATCTGCAGACTCCTGGGTTATCAGGGCATCGCTGTGGTCATGGAGGAACTGCTAAAGATTGTGAAGAGCTTGCTCCAAGGAACCATTCTCCAGTATGTGAAAACACTGATAGAGGTGATGCCCAAGATATGCCGCTTGCCCCGACATGAGTATGGCTCCCCAGGGATCCTGGAGTTCTTCCACCACCAGCTGAAGGACATCATTGAGTACGCAGAGCTCAAAACAGACGTGTTCCAGAGCCTGAGGGAAGTGGGCAATGCCATCCTCTTCTGCCTCCTCATAGAGCAAGCTCTGTCTCAGGAGGAGGTCTGCGATTTGCTCCATGCCGCACCCTTCCAAAACATCTTGCCTAGAGTCTACATCAAAGAGGGGGAGCGCCTGGAGGTCCGGATGAAACGTCTGGAAGCCAAGTATGCCCCGCTCCACCTGGTCCCTCTGATCGAGCGGCTGGGGACCCCTCAGCAAATCGCCATTGCTCGCGAGGGTGACCTCCTGACCAAGGAGCGGCTGTGCTGTGGCCTGTCCATGTTCGAGGTCATCCTGACCCGCATTCGGAGCTACCTGCAGGACCCCATCTGGCGGGGCCCACCGCCCACCAATGGCGTCATGCACGTCGATGAGTGTGTGGAGTTCCACCGGCTGTGGAGCGCCATGCAGTTCGTGTACTGCATCCCTGTGGGAACCAACGAGTTCACAGCTGAGCAGTGTTTCGGCGATGGCTTGAACTGGGCTGGTTGCTCCATCATTGTCCTGCTGGGCCAGCAGCGTCGCTTTGACCTGTTCGACTTCTGTTACCACCTGCTAAAAGTGCAGAGGCAGGACGGGAAGGATGAAATCATTAAGAATGTGCCCCTGAAGAAGATGGCCGACCGGATCAGGAAGTATCAGATCTTGAACAATGAGGTTTTTGCCATCCTGAACAAATACATGAAGTCCGTGGAGACAGACAGTTCCACTGTGGAGCATGTGCGCTGCTTCCAGCCACCCATCCACCAGTCCTTGGCCACCACTTGCTAA
ORF Protein Sequence MTTHVTLEDALSNVDLLEELPLPDQQPCIEPPPSSIMYQANFDTNFEDRNAFVTGIARYIEQATVHSSMNEMLEEGHEYAVMLYTWRSCSRAIPQVKCNEQPNRVEIYEKTVEVLEPEVTKLMKFMYFQRKAIERFCSEVKRLCHAERRKDFVSEAYLLTLGKFINMFAVLDELKNMKCSVKNDHSAYKRAAQFLRKMADPQSIQESQNLSMFLANHNRITQCLHQQLEVIPGYEELLADIVNICVDYYENKMYLTPSEKHMLLKVMGFGLYLMDGNVSNIYKLDAKKRINLSKIDKFFKQLQVVPLFGDMQIELARYIKTSAHYEENKSKWTCTQSSISPQYNICEQMVQIRDDHIRFISELARYSNSEVVTGSGLDSQKSDEEYRELFDLALRGLQLLSKWSAHVMEVYSWKLVHPTDKFCNKDCPGTAEEYERATRYNYTSEEKFAFVEVIAMIKGLQVLMGRMESVFNQAIRNTIYAALQDFAQVTLREPLRQAVRKKKNVLISVLQAIRKTICDWEGGREPPNDPCLRGEKDPKGGFDIKVPRRAVGPSSTQACQWSPRALFHPTGGTQGRRGCRSLLYMVRTMLESLIADKSGSKKTLRSSLDGPIVLAIEDFHKQSFFFTHLLNISEALQQCCDLSQLWFREFFLELTMGRRIQFPIEMSMPWILTDHILETKEPSMMEYVLYPLDLYNDSAYYALTKFKKQFLYDEIEAEVNLCFDQFVYKLADQIFAYYKAMAGSVLLDKRFRAECKNYGVIIPYPPSNRYETLLKQRHVQLLGRSIDLNRLITQRISAAMYKSLDQAISRFESEDLTSIVELEWLLEINRLTHRLLCKHMTLDSFDAMFREANHNVSAPYGRITLHVFWELNFDFLPNYCYNGSTNRFVRTAIPFTQEPQRDKPANVQPYYLYGSKPLNIAYSHIYSSYRNFVGPPHFKTICRLLGYQGIAVVMEELLKIVKSLLQGTILQYVKTLIEVMPKICRLPRHEYGSPGILEFFHHQLKDIIEYAELKTDVFQSLREVGNAILFCLLIEQALSQEEVCDLLHAAPFQNILPRVYIKEGERLEVRMKRLEAKYAPLHLVPLIERLGTPQQIAIAREGDLLTKERLCCGLSMFEVILTRIRSYLQDPIWRGPPPTNGVMHVDECVEFHRLWSAMQFVYCIPVGTNEFTAEQCFGDGLNWAGCSIIVLLGQQRRFDLFDFCYHLLKVQRQDGKDEIIKNVPLKKMADRIRKYQILNNEVFAILNKYMKSVETDSSTVEHVRCFQPPIHQSLATTC

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    Category Cat No. Products Name
    Target Antibody GM-Tg-g-IP2443-Ab Anti-CYFIP2 monoclonal antibody
    Target Antigen GM-Tg-g-IP2443-Ag CYFIP2 protein
    ORF Viral Vector pGMLV001652 Human CYFIP2 Lentivirus plasmid
    ORF Viral Vector vGMLV001652 Human CYFIP2 Lentivirus particle


    Target information

    Target ID GM-IP2443
    Target Name CYFIP2
    Gene ID 26999, 76884, 714984, 101101031, 479317, 518833, 100071224
    Gene Symbol and Synonyms 1500004I01Rik,6430511D02Rik,CYFIP2,DEE65,EIEE65,mKIAA1168,PIR121
    Uniprot Accession Q96F07
    Uniprot Entry Name CYFP2_HUMAN
    Protein Sub-location Introcelluar Protein
    Category Not Available
    Disease Not Available
    Gene Ensembl ENSG00000055163
    Target Classification Not Available

    Predicted to enable small GTPase binding activity. Involved in activation of cysteine-type endopeptidase activity; apoptotic process; and cell-cell adhesion. Located in perinuclear region of cytoplasm and synapse. Part of SCAR complex. Implicated in developmental and epileptic encephalopathy 65. [provided by Alliance of Genome Resources, Apr 2022]



    About GMVC

    GDU

    GMVC (GM Vector Core) is GeneMedi’s unique platform for QbD Viral vectors Processes development and manufacturing. In GMVC, our core expertise lies in the tailored production of viral vectors, including adeno-associated virus (AAV), lentivirus, and adenovirus. Our state-of-the-art facilities are equipped for scalable manufacturing, ensuring high-quality viral vector production to meet both research and therapeutic needs. Our expert team specializes in process development, leveraging innovative technology and extensive industry knowledge to provide clients with tailored solutions that exceed expectations. GMVC will be the ideal partner for scientists and healthcare professionals seeking reliable and efficient viral vector production services.